Clinical trials: DED
Kerato Conjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With DED
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 3 (NCT03616899)
- Testing
- KPI-121 Ophthalmic Suspension, Vehicle
- Where
- 81 sites in United States
- Volunteers
- 901 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye
Dry Eye Disease Study With Brimonidine
To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).
- Trial name
- NCT03418727
- Testing
- Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ocugen
Dry Eye
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months
- Trial name
- NCT06565650
- Testing
- Miebo, Saline
- Where
- 12 sites in United States
- Volunteers
- 216 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Disease (DED)
New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye
The goal of this prospective, non-randomized, non-comparative, monocentric PMCF study is to assess the performance of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA on DED at 6 months in 30…
- Trial name
- NCT06903741
- Testing
- T2769
- Where
- Bulgaria
- Volunteers
- 30 people
- Sponsor
- Laboratoires Thea
Dry Eye
Study of EBI-005 in Dry Eye Disease (DED)
This is a randomized, double masked study designed to evaluate the safety of EBI-005 5 mg/mL topical ophthalmic solution given three times daily (TID) compared to vehicle-control over a one year period in subjects with dry eye…
- Trial name
- EBI-005 (NCT02405039)
- Testing
- EBI-005
- Where
- 12 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eleven Biotherapeutics
Dry Eye Disease
Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)
A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease…
- Trial name
- NCT06178679
- Testing
- ST-100 (vezocolmitide), Vehicle
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- ORA, Inc.
Dry Eye Syndromes
Clinical Investigation to Assess the Efficacy and the Safety of VisuXL® Gel Administered in Patients Affected by Moderate DED
This is a post-market, european multicenter study. This is a randomized, cross-over, double blind study with competitive enrolment, aimed to enroll a total of 90 patients with a diagnosis of moderate dry eye disease (DED).
- Trial name
- NCT04485533
- Testing
- VisuXL® Gel, HYLO®
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 90 people
- Sponsor
- VISUfarma SpA
Dry Eye Disease
Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops
The primary objective is to evaluate the tolerability and efficacy of CWT-f-002 lubricant eye drops in the treatment of the signs and symptoms of dry eye disease.
- Trial name
- NCT05660681
- Testing
- glycerin 0.7%/PEG 400 0.3%, polyethylene glycol 400 0.4%/propylene glycol 0.3%
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Calm Water Therapeutics LLC
Keratitis
Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis
The proposed 3-month study is a prospective, open-label, multicentre, phase IV, proof of concept study. The study is designed to assess the effect on the quality of vision of IKERVIS® (1mg/mL ciclosporin) eye drops administered…
- Trial name
- FAST (NCT03237936)
- Testing
- 1mg/mL ciclosporin
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Santen SAS
Dry Eye Disease (DED)
Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease
The goal of this prospective, open, monocentric study is to evaluate the clinical efficacy of a new preservative-free combination of trehalose, sodium hyaluronate and NAAGA in 30 patients with chronic dry eye disease and…
- Trial name
- NCT07007702
- Testing
- T2769
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease (DED)
A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
The objective of this study is to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution twice a day (BID) and four times a day (QID) compared to placebo (vehicle) in the treatment of the signs and symptoms of dry…
- Trial name
- NCT07068958
- Testing
- 0.25% RCI001 Ophthalmic Solution
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Evaporative Dry Eye Disease
Evaluation of MAF-1217 in Patients With DED
This is a pre-market, multicentre, double-blind, randomized, crossover, non-inferiority study comparing the efficacy of MAF-1217 and Cationorm® in adult patients with evaporative DED.
- Trial name
- NCT03833882
- Testing
- MAF1217, Cationorm
- Where
- 2 sites in Italy
- Volunteers
- 72 people
- Sponsor
- VISUfarma SpA
Dry Eye
Performance and Safety of T2769 in DED
To demonstrate the non-inferiority of T2769 compared to Vismed® Multi in terms of total ocular surface staining (Oxford score) after 35 days of treatment. To evaluate the performance and safety of T2769 versus Vismed® Multi.
- Trial name
- NCT05965778
- Testing
- T2769, Vismed® Multi
- Where
- France
- Volunteers
- 251 people
- Sponsor
- Laboratoires Thea
Dry Eye Syndromes
Efficacy of T2259 in DED
The purpose of this study is to compare the performance and safety of T2259 versus Vismed Multi in dry eye patients with superficial keratitis.
- Trial name
- NCT03874429
- Testing
- T2259, Vismed multi
- Where
- France
- Volunteers
- 101 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.
- Trial name
- NCT03292809
- Testing
- CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
- Where
- 9 sites in United States
- Volunteers
- 328 people
- Sponsor
- Novaliq GmbH
Dry Eye Disease
Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic solution is more effective than vehicle in treating…
- Trial name
- RELIEF (NCT05896670)
- Testing
- licaminlimab, vehicle of OCS-02, Artificial tears
- Where
- 5 sites in United States
- Volunteers
- 122 people
- Sponsor
- Oculis
Dry Eye Disease (DED), Cataract Surgery
POST CATARACT SURGERY DRY EYE DISEASE
Cataract surgery is one of the most frequent and successful interventions currently undertaken in medicine. However, a significant number of patients who underwent cataract surgery still complain about postoperative symptoms…
- Trial name
- NCT07715266
- Testing
- NOX-01
- Where
- 2 sites in Spain
- Volunteers
- 33 people
- Sponsor
- NOXELIS
Keratitis, Autoimmunity
A Clinical Study to Evaluate the Safety and Effectiveness of MSCohi-O Lens in the Treatment of Immune-related Ocular Surface Diseases.
Immune-related ocular surface diseases are a kind of non-infectious eye disease pedigree, which is mediated by abnormal immune system function and characterized by ocular surface tissue damage.
- Conditions
- Keratitis, Autoimmunity, Dry Eye Disease (DED)
- Trial name
- NCT07902687
- Testing
- MSCohi-O lens
- Volunteers
- 20 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
Dry Eye Disease (DED)
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.
- Trial name
- NCT04523142
- Testing
- CyclASol Ophthalmic Solution
- Where
- 14 sites in United States
- Volunteers
- 202 people
- Sponsor
- Novaliq GmbH
Dry Eye Disease, Meibomian Gland Dysfunction
Feasibility of IPL Combined With RF for Treatment of DED Due to MGD
The purpose of this single-arm pilot study is to evaluate the feasibility and safety of combination therapy of intense pulsed light (IPL) and (Radiofrequency) RF for treatment of Dry eye disease (DED) due to Meibomian gland…
- Trial name
- NCT05487547
- Testing
- IPL_RF_MGX
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Lumenis Be Ltd.